

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Joji Nakayama, President and CEO  
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)  
Please address inquiries to Toshiaki Sai, Corporate Officer,  
Vice President, Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com/>

**Announcement Regarding the Launch Date in Japan for Mema<sup>®</sup> 5mg, 10mg and 20mg  
Tablets for the Treatment of Alzheimer's Disease**

**TOKYO, Japan (March 16, 2011)** — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), today announced that it has postponed the launch in Japan of Mema<sup>®</sup> 5mg, 10mg and 20mg Tablets (generic name: Memantine Hydrochloride) given once daily for the treatment of moderate to severe Alzheimer's Disease. The launch was scheduled for March 18; however, in order to ensure a stable supply of Mema to patients in light of the March 11 Tohoku Pacific Offshore Earthquake, the launch has been postponed.

Daiichi Sankyo intends to once again move forward with preparations for Mema's launch as soon as it is possible, and will make an announcement at that time.

###